Brief: Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®

Bolt Biotherapeutics

05/12/2023 12:39

Dec 5 (Reuters) - Bolt Biotherapeutics Inc  BOLT.O :
    * BOLT BIOTHERAPEUTICS ENROLLS FIRST PATIENT IN PHASE 2
CLINICAL
STUDY EVALUATING BDC-1001 IN PATIENTS WITH HER2-POSITIVE BREAST
CANCER PREVIOUSLY TREATED WITH ENHERTU®

Source text for Eikon:  ID:nGNX4Z9S3m 
Further company coverage:  BOLT.O 

 ((Reuters.Briefs@thomsonreuters.com;))